Paragon Biosciences

11/03/2022

Our portfolio company Emalex Biosciences recently closed an impressive $250 million funding. Read more:

Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors CHICAGO—November 3, 2022—Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clini...

08/16/2022

We are moving from an era of treating diseases to curing them. Listen to our CEO Jeff Aronin as he describes how Paragon is leading the biology revolution and changing the landscape of life science innovation: https://youtu.be/B8z9f13QCuQ

06/28/2022

Our latest portfolio company, CiRC Biosciences, is on a mission to one day restore vision for people with certain eye diseases. Sai Chavala, M.D., co-founder and chief scientific officer of CiRC, describes the unique cell therapy work taking place at CiRC and how the technology may be applied to other diseases and conditions: https://youtu.be/PIEdErRN3mM

06/09/2022

Read our first half 2022 newsletter covering the recent outstanding achievements of Paragon and its portfolio companies: https://mailchi.mp/73f8d7bf8817/paragon-biosciences-first-half-2022-newsletter

Don’t’ forget to subscribe!

At the American Academy of Neurology’s (ANN) annual meeting, Emalex Biosciences presented an abstract on its phase 2B study positive topline results for a potential therapy to treat pediatric patients with Tourette syndrome. Study data received last November showed statistically significant and cl...

04/25/2022

04/01/2022

Great news!

Findings show investigational drug reduces tics by 30%; Data presentation April 5

03/07/2022

Paragon is a global life sciences leader that creates, builds and funds innovative biology-based companies. We identify unmet needs and use biology to accelerate scientific breakthroughs to solve some of society’s most challenging problems.

Learn more about us and the work being done by our portfolio companies: https://youtu.be/maWtG-B3B3k

03/01/2022

Emalex Biosciences, a Paragon portfolio company, recently completed a license agreement with East Carolina University for the patent rights of an investigational, first-in class dopamine-1 (D1) receptor antagonist to potentially advance clinical studies for the treatment of Restless Legs Syndrome with augmentation (RLSa). Approximately 5%-10% of the general population is impacted by RLS, making it the most common movement disorder. RLSa is the worsening of RLS symptoms despite treatment with conventional therapies.

Read more:

License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders

02/22/2022

: Fantastic news from our portfolio company Emalex Biosciences. Its topline results from a Phase 2b clinical study evaluating a first-in-class investigational therapy for pediatric patients with are POSITIVE! Read more about the study results and what’s next here:

Statistically significant, clinically meaningful results obtained on the primary and multiple secondary efficacy endpoints; ecopipam well tolerated in the study

02/15/2022

Castle Creek Biosciences is continuing its important work for an investigational gene therapy treatment for recessive dystrophic epidermolysis bullosa, with a Phase 3 clinical trial in progress. Expanding on its innovative cell and gene therapy platform, Castle Creek recently acquired Novavita Thera, a preclinical gene therapy company focused on rare liver and metabolic diseases. This comes on the heels of Castle Creek entering a research collaboration with Mayo Clinic to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome. Read more: https://castlecreekbio.com/category/press-release/

Castle Creek is a portfolio company of Paragon.

Research to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments